The 2-Minute Rule for N8-Acetylspermidine dihydrochloride
Kantarjian et al53 assessed the efficacy and safety of dasatinib, as when compared with imatinib, for the very first-line treatment of CML-CP. 5 hundred and nineteen people with newly diagnosed CML-CP were being randomly assigned to obtain dasatinib in a dose of 100 mg when every day (259 patients) or imatinib in a dose of four hundred mg as soon a